Archeon announced today that it completed a Series A financing round worth more than $6 million (€5.5 million).
Besançon, France-based Archeon said in a news release that it will use the funds to speed up access to new markets, including North America, and to expand its range of medical ventilation devices for pre-hospital and hospital uses.
Archeon develops the EOlife unit, a device for assisting manual ventilation in cases of cardiorespiratory arrest. The company designed the system to measure and analyze a patient’s respiratory variables in real-time to deliver enough oxygen while avoiding hyperventilation.
The company also develops the PulmonAIR device, which it aims to make the first fully automated emergency ventilator for managing respiratory diseases.
Funds will also be used to help Archeon expand its current team of 17 people with newly created research and development and marketing jobs.
“We would like to thank all of the private and public investors for their support and trust,” Archeon Co-Founder Pierre Edouard Saillard said in the release. “Our aim is to become the leaders in smart ventilation. … Our EOlife solution has the potential to revolutionize ventilation in and outside hospitals and to save lives when treating patients in cardiorespiratory arrest.”
Karot Capital, Majycc eSanté Invest and Daphni led the funding round. It was also supported by the European Regional Development Fund (ERDF – European Social Fund for Franche-Comté and Massif du Jura), and by Bpifrance.